Published in Ann Intern Med on May 15, 1991
NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci U S A (2001) 1.31
Portal hypertension and gastrointestinal bleeding: diagnosis, prevention and management. World J Gastroenterol (2013) 1.03
Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis. World J Hepatol (2014) 0.86
Prevention and management of gastroesophageal varices in cirrhosis. Int J Hepatol (2012) 0.78
Liver disease. Postgrad Med J (1994) 0.76
Effects of propranolol or propranolol plus isosorbide-5-mononitrate on variceal pressure in schistosomiasis. World J Gastroenterol (2013) 0.75
Acute effect of propranolol and isosorbide-5-mononitrate administration on renal blood flow in cirrhotic patients. Gut (1998) 0.75
Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension. ISRN Hepatol (2013) 0.75
Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension. Dig Dis Sci (2002) 0.75
Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin, on carbon tetrachloride-induced hepatic injury in rats. Inflammopharmacology (2010) 0.75
Long term management of oesophageal varices. Drugs (1992) 0.75
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology (2001) 6.88
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med (2001) 6.38
Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet (1995) 6.06
Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med (1999) 5.89
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (1999) 5.64
Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 5.09
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (1988) 4.32
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation (2001) 3.96
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology (1998) 3.62
Ramipril and the development of diabetes. JAMA (2001) 3.38
The treatment of portal hypertension: a meta-analytic review. Hepatology (1995) 3.11
Compensated cirrhosis: natural history and prognostic factors. Hepatology (1987) 3.01
Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology (1990) 2.99
Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology (1996) 2.96
Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol (2001) 2.73
Effects of somatostatin on renal function in cirrhosis. Gastroenterology (1992) 2.68
Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology (2000) 2.57
Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology (1995) 2.47
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation (2001) 2.30
Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology (1994) 2.27
Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology (2000) 2.22
Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol (2000) 2.22
Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis (1999) 2.15
A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology (2001) 2.14
S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol (1999) 2.14
Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology (1998) 2.10
Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology (1996) 2.00
Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology (1993) 1.97
Beta-blockade with propranolol and hepatic artery blood flow in patients with cirrhosis. Hepatology (1989) 1.97
Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol (1999) 1.92
Circulating levels of endothelin in cirrhosis. Gastroenterology (1993) 1.91
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J (2004) 1.90
Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol (2001) 1.89
Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet (1991) 1.88
Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology (1998) 1.87
Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet (1989) 1.86
Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol (1986) 1.84
Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology (1998) 1.83
Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide. Hepatology (1993) 1.79
Gastric mucosal vascular ectasias causing bleeding in cirrhosis. A distinct entity associated with hypergastrinemia and low serum levels of pepsinogen I. Gastroenterology (1987) 1.77
Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology (1988) 1.76
Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol (1998) 1.76
Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology (1998) 1.74
Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology (1988) 1.74
Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology (1996) 1.68
Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology (1983) 1.67
Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury. Hepatology (1990) 1.67
Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology (2000) 1.67
Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology (1993) 1.67
Fulminant hepatic failure. Lancet (1997) 1.66
In vitro and in vivo activation of rat hepatic stellate cells results in de novo expression of L-type voltage-operated calcium channels. Hepatology (2001) 1.66
Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology (1999) 1.64
Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. Gastroenterology (1996) 1.64
Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology (2001) 1.62
Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology (1999) 1.62
Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology (1998) 1.60
The lung in patients with cirrhosis. J Hepatol (1990) 1.59
Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis (1976) 1.59
Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet (1993) 1.57
Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Gastroenterology (1992) 1.57
Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls. J Hepatol (1998) 1.55
Increased nitric oxide-dependent vasorelaxation in aortic rings of cirrhotic rats with ascites. Hepatology (1994) 1.54
Steady-state extrarenal sorbitol clearance as a measure of hepatic plasma flow. Gastroenterology (1988) 1.53
Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis. J Hepatol (2000) 1.53
Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology (1990) 1.52
Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. J Hepatol (1994) 1.49
Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol (1998) 1.49
Cyclosporine-associated mutism in liver transplant patients. Neurology (1996) 1.49
A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol (2001) 1.49
Testing non-linearity and directedness of interactions between neural groups in the macaque inferotemporal cortex. J Neurosci Methods (1999) 1.49
Endoscopic sclerotherapy in upper gastrointestinal bleeding due to the Mallory-Weiss syndrome. Am J Gastroenterol (1994) 1.48
Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology (1998) 1.47
Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology (1992) 1.45
Limitations of laser-Doppler velocimetry and reflectance spectrophotometry in estimating gastric mucosal blood flow. Am J Physiol (1992) 1.43
Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology (1997) 1.43
Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut (2008) 1.43
Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology (1992) 1.42
Economic outcomes analysis of stenting versus percutaneous transluminal coronary angioplasty for patients with coronary artery disease in Japan. J Invasive Cardiol (2000) 1.41